跳转至内容
Merck
CN
  • Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research (2020-09-25)
Andrea M Pesch, Nicole H Hirsh, Benjamin C Chandler, Anna R Michmerhuizen, Cassandra L Ritter, Marlie P Androsiglio, Kari Wilder-Romans, Meilan Liu, Christina L Gersch, José M Larios, Lori J Pierce, James M Rae, Corey W Speers
摘要

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression-free survival for metastatic, estrogen receptor-positive (ER+) breast cancers, but their role in the nonmetastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radiotherapy in multiple preclinical breast cancer models. Transcriptomic and proteomic analyses were used to identify significantly altered pathways after CDK4/6i. Clonogenic assays were used to quantify the radiotherapy enhancement ratio (rER). DNA damage was quantified using γH2AX staining and the neutral comet assay. DNA repair was assessed using RAD51 foci formation and nonhomologous end joining (NHEJ) reporter assays. Orthotopic xenografts were used to assess the efficacy of combination therapy. Palbociclib significantly radiosensitized multiple ER+ cell lines at low nanomolar, sub IC50 concentrations (rER: 1.21-1.52) and led to a decrease in the surviving fraction of cells at 2 Gy (P < 0.001). Similar results were observed in ribociclib-treated (rER: 1.08-1.68) and abemaciclib-treated (rER: 1.19-2.05) cells. Combination treatment decreased RAD51 foci formation (P < 0.001), leading to a suppression of homologous recombination activity, but did not affect NHEJ efficiency (P > 0.05). Immortalized breast epithelial cells and cells with acquired resistance to CDK4/6i did not demonstrate radiosensitization (rER: 0.94-1.11) or changes in RAD51 foci. In xenograft models, concurrent palbociclib and radiotherapy led to a significant decrease in tumor growth. These studies provide preclinical rationale to test CDK4/6i and radiotherapy in women with locally advanced ER+ breast cancer at high risk for locoregional recurrence.

材料
货号
品牌
产品描述

Roche
cOmplete蛋白酶抑制剂Cocktail, Tablets provided in glass vials
登录查看公司和协议定价
货号包装规格是否有货价格数量
20 tabs
有货
详情...
¥5,040.79
3 x 20 tabs
有货
详情...
¥14,413.22
Sigma-Aldrich
抗磷酸组蛋白H2A.X(Ser139)抗体,克隆JBW301, clone JBW301, Upstate®, from mouse
登录查看公司和协议定价
货号包装规格是否有货价格数量
25 μg
预计发货时间 2025年3月07日
详情...
¥1,455.13
200 μg
预计发货时间 2025年3月10日
详情...
¥8,607.28
Sigma-Aldrich
L-乳酸钠, ~98%
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 g
有货
详情...
¥1,104.73
10 g
有货
详情...
¥1,600.37
50 g
有货
详情...
¥5,560.14
Sigma-Aldrich
AZD-7762 hydrochloride, ≥98% (HPLC)
登录查看公司和协议定价
货号包装规格是否有货价格数量
5 mg
请联系客服了解存货情况
¥1,272.11
25 mg
预计发货时间 2025年3月26日
详情...
新价格,新优惠!
¥3,865.78
Sigma-Aldrich
抗-RAD51抗体, from rabbit, purified by affinity chromatography
登录查看公司和协议定价
货号包装规格是否有货价格数量
100 μL
预计发货时间 2025年3月18日
详情...
针对您的靶标提供了无防腐剂重组抗体。试用 ZRB1492
¥4,985.59